Nimenrix Dosing and Administration

Nimenrix (Meningococcal groups A, C, W135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neiserria meningitidis serogroups A, C, W135 and Y.*,†,1

Nimenrix dosing schedule:*,†,1

dosing_schedule

Route of administration1

  • Immunisation should be carried out by intramuscular injection only
  • The recommended injection site is the anterolateral aspect of the thigh in infants. The anterolateral aspect of the thigh or deltoid muscle is the recommended injection site for individuals from 1 year of age

*See prescribing information for further information

Nimenrix should be used in accordance with official recommendations

Administration

Nimenrix™ is available as a single pack with two needles for reconstitution and administration (23G blue and 25G orange, 25mm).2 Nimenrix comes as a powder in a vial, with a solvent for solution for injection in a pre-filled syringe. These components require reconstitution prior to administration.1

admin

Visuals adapted from visuals sourced from vecteezy.com.

Click here to download the Nimenrix administration guide

How should Nimenrix be stored?1

Before reconstitution – Nimenrix should be stored in the refrigerator between 2°C and 8°C in its original packaging. It has a shelf life of 4 years, but the expiry date on the packaging should always be checked prior to use. 

After reconstitution – Nimenrix should be used promptly following reconstitution. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If the vaccine is not used within 8 hours, it should not be administered.

References

1. Nimenrix. Summary of Product Characteristics, United Kingdom, Pfizer Ltd. Available here
2. Pfizer data on file, February 2020.

Prescribing Information
Nimenrix™ prescribing information.

 

PP-NIM-GBR-0219.  June 2020